Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
about
Therapeutic potential of resveratrol in Alzheimer's diseaseTherapeutic approach to FSGS in children.hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.The role of nuclear receptors in the kidney in obesity and metabolic syndromePPAR-gamma agonists and diabetic nephropathy.The effects of thiazolidinediones on blood pressure levels - a systematic review.Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblastsMicroRNA-27a Induces Mesangial Cell Injury by Targeting of PPARγ, and its In Vivo Knockdown Prevents Progression of Diabetic NephropathyRosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.PPARs and the kidney in metabolic syndrome.Peroxisome proliferator-activated receptors in diabetic nephropathy.PPARγ and chronic kidney disease.PPAR-γ agonism for cardiovascular and renal protection.Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2).The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells.Insulin signaling to the glomerular podocyte is critical for normal kidney function.Peroxisome proliferator-activated receptor γ Pro12Ala polymorphism decrease the risk of diabetic nephropathy in type 2 diabetes: a meta analysis.Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation.Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice.Renal PPARγ mRNA expression increases with impairment of renal function in patients with chronic kidney disease.Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: panacea or another Pandora's box?Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction.PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.Reduction of proteinuria by rosiglitazone in non-diabetic renal disease.Rosiglitazone treatment attenuates expression of inflammatory hallmarks in the remaining kidney following contralateral nephrectomy.Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats.Thiazolidinediones and progression of renal disease in patients with diabetes.Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
P2860
Q30855117-B1995126-4A24-413E-852C-D3C9544EEA4FQ35614311-AD8A82B9-1839-4B2E-AC12-878097FB4AA5Q35677086-B858A8F6-507C-41E0-884A-B7349714B31CQ36068458-C307FAAC-1332-4449-AF6C-6CCAFF146043Q36250127-B4F12C22-70B9-49E3-A3AA-BF7F365125F9Q36326399-A5E540FC-D164-4E74-97F9-40E8933A18D2Q36545395-51A17743-CC33-4E66-AB13-9FB9C9E9ED04Q36577073-726BF3A5-863D-4B9B-ADCE-E9FDD623D52EQ36734442-658BBA7D-2335-4928-8739-AD1CB3596CF7Q36906818-BD87DFB9-2C17-487D-AE93-6B802295CD7EQ36956727-DACC7023-DD00-4859-8924-373E18ADACAAQ37072216-51ED21F0-869B-4FF9-8E2C-70DCEFB041BEQ37412297-F289214B-A41E-4181-8250-A180A7F8B169Q37777055-BF2CD796-3483-469F-992E-CCEAF4722CE9Q37788729-B6F9232E-B77B-4196-80E8-D6EB14BCB6F6Q40251913-8207DB9A-5A51-4C37-BCE8-3C4A8DD29C83Q40561968-970692A1-855A-42C6-AA7C-F3EF11D544FBQ42110064-22AD4DE9-43BD-4558-A142-D17F07153DD4Q42364753-40A34646-5F2E-4EAA-BB8C-5094B2DC080CQ42518271-527529CB-6D7C-4E43-B314-B1BC5EA7279AQ42641988-9FE6E519-1E8F-45E8-95EF-9973C3F32B28Q42840206-0AE5117C-7D75-414C-93B2-F23A15AF00A0Q43986735-2A6AC352-F6B3-4FDD-A0BA-73F2C356B16AQ46163216-E740323E-4AFD-497F-895B-0DA57571025CQ46484275-7CEA8805-C1FA-4B5D-BAB8-3F2FD2CF4113Q46805468-241C3F00-522A-4B83-806E-2A4F9C2C2F06Q46920574-681B1FAF-6D2D-4F70-B6F4-1BAD0130DB19Q46921305-88977AF7-5889-4474-AB2A-4BBE0C84DC2AQ46939789-6A2F6685-FD1F-4B43-8BE7-C70209564CD3Q53579919-AA9DD7F9-0BC0-4AE1-90F1-A3B1704503A1
P2860
Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Expression and function of per ...... ptor-gamma in mesangial cells.
@ast
Expression and function of per ...... ptor-gamma in mesangial cells.
@en
type
label
Expression and function of per ...... ptor-gamma in mesangial cells.
@ast
Expression and function of per ...... ptor-gamma in mesangial cells.
@en
prefLabel
Expression and function of per ...... ptor-gamma in mesangial cells.
@ast
Expression and function of per ...... ptor-gamma in mesangial cells.
@en
P2093
P356
P1433
P1476
Expression and function of per ...... ptor-gamma in mesangial cells.
@en
P2093
P304
P356
10.1161/01.HYP.37.2.722
P407
P433
P577
2001-02-01T00:00:00Z